Amicus Therapeutics (NASDAQ:FOLD) has seen a rise of 443,845 shares or 2.2% in the short interest. The remaining shorts are 17.5% of the total floated shares. The net short interest, as on June 15,2016, stood at 21,075,941 shares and the stocks days to cover will be 8 by factoring in the average per day volume of 2,574,734 shares. On May 31,2016, 20,632,096 shares were shorted. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Amicus Therapeutics (NASDAQ:FOLD): The stock opened at $5.53 on Friday but the bulls could not build on the opening and the stock topped out at $5.75 for the day. The stock traded down to $5.44 during the day, due to lack of any buying support eventually closed down at $5.45 with a loss of -7.78% for the day. The stock had closed at $5.91 on the previous day. The total traded volume was 4,063,230 shares.
The company shares have dropped -60.01% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $6.57 and the 200 Day Moving Average price is recorded at $7.39.
Amicus Therapeutics (NASDAQ:FOLD) has tumbled 3.02% during the past week and has dropped 22.81% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.42%. Amicus Therapeutics (NASDAQ:FOLD) has underperformed the index by 20.47% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.